{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:49:37Z","timestamp":1792054177632,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82474394"],"award-info":[{"award-number":["82474394"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["2023YFS0506"],"award-info":[{"award-number":["2023YFS0506"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.psychres.2026.117270","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T23:43:53Z","timestamp":1781048633000},"page":"117270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Post-marketing safety surveillance of the novel muscarinic antipsychotic Xanomeline-Trospium for schizophrenia: A comparative disproportionality analysis against olanzapine based on FAERS data"],"prefix":"10.1016","volume":"364","author":[{"given":"Yining","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyue","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3221-0092","authenticated-orcid":false,"given":"Junguo","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.psychres.2026.117270_bib0001","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2344\/0003-3006-57.4.150","article-title":"Nausea, vomiting, and hiccups: a review of mechanisms and treatment","volume":"57","author":"Becker","year":"2010","journal-title":"Anesth. Prog."},{"issue":"8","key":"10.1016\/j.psychres.2026.117270_bib0002","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.psychres.2026.117270_bib0003","unstructured":"C.E.R.S.A.S.L.L., 2024. COBENFYTM (xanomeline and trospium chloride) capsules, for oral use."},{"key":"10.1016\/j.psychres.2026.117270_bib0004","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3389\/fnins.2020.00542","article-title":"Subcortical dopamine and cognition in schizophrenia: looking beyond psychosis in preclinical models","volume":"14","author":"Conn","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.psychres.2026.117270_bib0005","article-title":"Discrepancies in regulations in post-marketing safety surveillance of drug-device combination products in the EU and US: a review","volume":"5","author":"D'Souza","year":"2025","journal-title":"Front. Drug Saf. Regul."},{"key":"10.1016\/j.psychres.2026.117270_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.112989","article-title":"Muscarinic M1 and M4 receptors: hypothesis driven drug development for schizophrenia","volume":"288","author":"Dean","year":"2020","journal-title":"Psychiatr. Res."},{"issue":"7","key":"10.1016\/j.psychres.2026.117270_bib0007","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2165\/00003088-200544070-00003","article-title":"Clinical pharmacokinetics of trospium chloride","volume":"44","author":"Doroshyenko","year":"2005","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.psychres.2026.117270_bib0008","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/0022034509356055","article-title":"Clozapine: agonistic and antagonistic salivary secretory actions","volume":"89","author":"Ekstr\u00f6m","year":"2010","journal-title":"J. Dent. Res."},{"issue":"2","key":"10.1016\/j.psychres.2026.117270_bib0009","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case-non-case studies: principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapie"},{"issue":"2","key":"10.1016\/j.psychres.2026.117270_bib0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/ab.22061","article-title":"Exploring predictors of aggressive intrusive thoughts and aggressive scripts: similarities and differences in phenomenology","volume":"49","author":"Fernandez","year":"2023","journal-title":"Aggres. Behav."},{"issue":"9","key":"10.1016\/j.psychres.2026.117270_bib0011","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1044\/2023_JSLHR-22-00739","article-title":"Identifying medications underlying communication atypicalities in psychotic and affective disorders: a pharmacovigilance study within the FDA adverse event reporting system","volume":"66","author":"Fusaroli","year":"2023","journal-title":"J. Speec. Lang. Hear Res."},{"issue":"5","key":"10.1016\/j.psychres.2026.117270_bib0012","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions : a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.psychres.2026.117270_bib0013","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/ern.09.143","article-title":"Effect of second-generation antipsychotics on cognition: current issues and future challenges","volume":"10","author":"Hill","year":"2010","journal-title":"Expert. Rev. Neurother."},{"issue":"Suppl 8A","key":"10.1016\/j.psychres.2026.117270_bib0014","article-title":"Central neurocircuitry associated with emesis","volume":"111","author":"Hornby","year":"2001","journal-title":"Am. J. Med."},{"issue":"12","key":"10.1016\/j.psychres.2026.117270_bib0015","article-title":"Exploring cognitive deficits and neuromodulation in Schizophrenia: a narrative review","volume":"60","author":"Hung","year":"2024","journal-title":"Med. (Kaunas)"},{"key":"10.1016\/j.psychres.2026.117270_bib0016","volume":"1","author":"Kahn","year":"2015","journal-title":"Schizophrenia. Nat. Rev. Dis. Primer."},{"issue":"19","key":"10.1016\/j.psychres.2026.117270_bib0017","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","article-title":"Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial","volume":"296","author":"Kaplan","year":"2006","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.psychres.2026.117270_bib0018","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.24m15497","article-title":"Safety and tolerability of xanomeline and trospium chloride in schizophrenia: pooled results from the 5-week, randomized, double-blind, placebo-controlled emergent trials","volume":"86","author":"Kaul","year":"2025","journal-title":"J. Clin. Psychiatr."},{"issue":"10422","key":"10.1016\/j.psychres.2026.117270_bib0019","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (Xanomeline-Trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"Lancet"},{"issue":"10422","key":"10.1016\/j.psychres.2026.117270_bib0020","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline\u2013trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"The Lance."},{"issue":"8","key":"10.1016\/j.psychres.2026.117270_bib0021","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and safety of Xanomeline-trospium chloride in schizophrenia: a randomized clinical trial","volume":"81","author":"Kaul","year":"2024","journal-title":"JAMA Psychiatr."},{"issue":"9","key":"10.1016\/j.psychres.2026.117270_bib0022","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American psychiatric association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.psychres.2026.117270_bib0023","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.1038\/sj.bjp.0707604","article-title":"Agonist-selective mechanisms of GPCR desensitization","volume":"153","author":"Kelly","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.psychres.2026.117270_bib0024","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.psychres.2026.117270_bib0025","doi-asserted-by":"crossref","unstructured":"Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., Keefe, R.S.E., Davis, S.M., Davis, C.E., Lebowitz, B.D., Severe, J., Hsiao, J.K., 2005b Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. 353 (12), 1209\u20131223.","DOI":"10.1056\/NEJMoa051688"},{"key":"10.1016\/j.psychres.2026.117270_bib0026","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.psychres.2016.05.005","article-title":"The violent content in attenuated psychotic symptoms","volume":"242","author":"Marshall","year":"2016","journal-title":"Psychiatr. Res."},{"issue":"2","key":"10.1016\/j.psychres.2026.117270_bib0027","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","article-title":"Schizophrenia-an overview","volume":"77","author":"McCutcheon","year":"2020","journal-title":"JAMA Psychiatr."},{"issue":"3","key":"10.1016\/j.psychres.2026.117270_bib0028","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s13311-017-0552-9","article-title":"Clozapine as a model for antipsychotic development","volume":"14","author":"Nucifora","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"10","key":"10.1016\/j.psychres.2026.117270_bib0029","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","article-title":"Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias","volume":"30","author":"Pariente","year":"2007","journal-title":"Drug Saf."},{"issue":"9","key":"10.1016\/j.psychres.2026.117270_bib0030","first-page":"638","article-title":"Schizophrenia: overview and treatment options","volume":"39","author":"Patel","year":"2014","journal-title":"Pharma. Therapeut."},{"issue":"9","key":"10.1016\/j.psychres.2026.117270_bib0031","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/appi.ajp.21101083","article-title":"Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia","volume":"179","author":"Paul","year":"2022","journal-title":"Am. J. Psychiatr."},{"issue":"6","key":"10.1016\/j.psychres.2026.117270_bib0032","doi-asserted-by":"crossref","DOI":"10.5498\/wjp.v15.i6.105409","article-title":"Targeting muscarinic receptors in schizophrenia treatment: novel antipsychotic xanomeline\/trospium chloride","volume":"15","author":"Pej\u010di\u0107","year":"2025","journal-title":"World J. Psychiatr."},{"issue":"3","key":"10.1016\/j.psychres.2026.117270_bib0033","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/cpt.3701","article-title":"FDA adverse event Reporting System (FAERS) essentials: a guide to understanding, applying, and interpreting adverse event data reported to FAERS","volume":"118","author":"Potter","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.psychres.2026.117270_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2025.1630574","article-title":"Early outpatient clinical experience with xanomeline and trospium chloride for schizophrenia: a case report","volume":"16","author":"Price","year":"2025","journal-title":"Front. Psychiatr."},{"issue":"10","key":"10.1016\/j.psychres.2026.117270_bib0035","doi-asserted-by":"crossref","first-page":"543","DOI":"10.5414\/CPP42543","article-title":"Absorption pattern of trospium chloride along the human gastrointestinal tract assessed using local enteral administration","volume":"42","author":"Schr\u00f6der","year":"2004","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.psychres.2026.117270_bib0036","doi-asserted-by":"crossref","first-page":"2","DOI":"10.9758\/cpn.24.1253","article-title":"Xanomeline-Trospium (Cobenfy (TM)) for Schizophrenia: a review of the literature","volume":"23","author":"Smith","year":"2025","journal-title":"Clin. Psychopharmacol. Neurosci."},{"issue":"3","key":"10.1016\/j.psychres.2026.117270_bib0037","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin. Pharmacokine."},{"issue":"12","key":"10.1016\/j.psychres.2026.117270_bib0038","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1038\/s41380-023-02138-4","article-title":"Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019","volume":"28","author":"Solmi","year":"2023","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.psychres.2026.117270_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2026.117162","article-title":"A real-world pharmacovigilance study of Xanomeline-Trospium events in the FDA adverse event reporting system (FAERS)","volume":"361","author":"Song","year":"2026","journal-title":"Psychiatr. Res."},{"issue":"4","key":"10.1016\/j.psychres.2026.117270_bib0040","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1176\/appi.ajp.20240321","article-title":"Continuous dopamine D (2) receptor blockade and long-term outcome in first-episode schizophrenia","volume":"182","author":"Tiihonen","year":"2025","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.psychres.2026.117270_bib0041","article-title":"Real-world effectiveness and safety of xanomeline and trospium for treatment-resistant schizophrenia in a state hospital system","volume":"16","author":"Vadiei","year":"2025","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.psychres.2026.117270_bib0042","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fnins.2013.00220","article-title":"A cholinergic hypothesis of the unconscious in affective disorders","volume":"7","author":"Vakalopoulos","year":"2013","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.psychres.2026.117270_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1421554","article-title":"The potential of muscarinic M (1) and M (4) receptor activators for the treatment of cognitive impairment associated with schizophrenia","volume":"15","author":"Yohn","year":"2024","journal-title":"Front. Psychiatry."},{"issue":"12","key":"10.1016\/j.psychres.2026.117270_bib0044","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.tips.2022.09.006","article-title":"Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic","volume":"43","author":"Yohn","year":"2022","journal-title":"Trend. Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.psychres.2026.117270_bib0045","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/0922-4106(94)90047-7","article-title":"Clozapine is a potent and selective muscarinic M4 receptor agonist","volume":"269","author":"Zorn","year":"1994","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2026.117270_bib0046","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"Zucker","year":"2020","journal-title":"Biol Sex Differ"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178126003306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178126003306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:30:06Z","timestamp":1792053006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178126003306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":46,"alternative-id":["S0165178126003306"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2026.117270","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-marketing safety surveillance of the novel muscarinic antipsychotic Xanomeline-Trospium for schizophrenia: A comparative disproportionality analysis against olanzapine based on FAERS data","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2026.117270","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117270"}}